Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

Hormone therapy can make a big difference for men with recurrent or metastatic prostate cancer. But it isn't a cure. Its effects are limited and the side effects can be difficult to cope with.

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

ANDROGEN deprivation therapy (ADT) has been the cornerstone of treatment for advanced castration-sensitive prostate cancer ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

Sep. 4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay ...

The global hormone-sensitive advanced prostate cancer treatment market is projected to achieve a valuation of USD 12.44 ...

Prostate cancer is Australia's most commonly diagnosed ... delaying the need for hormone therapy or chemotherapy. Stereotactic radiation therapy is delivered daily, with painless radiation beams.